Sign up online today & collaborate
or click here to find out more
Novartis says late-stage clinical data show that its cancer drug Afinitor extended progression-free survival in patients with advanced nonfunctional neuroendocrine tumours (NET) of gastrointestinal or lung origin.
A Phase III trial of the drug - called RADIANT-4 - met its primary endpoint by demonstrating significant extension of progression-free survival (PFS) compared to placebo plus best supportive care.For more click here
Source: Pharma Times